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LMP2A is consistently detected in Hodgkin's lymphoma, nasopharyngeal carcinoma and has also been detected in Burkitt's lymphoma.
Interestingly, LMP2A is detected in the absence of the transcriptional activator EBNA2, suggesting that an alternative mechanism is responsible
for LMP2A expression. The intracellular domain of Notch (Notch-IC) and EBNA2 are functional homologs and recent microarray analysis
indicates that LMP2A may constitutively activate the Notch pathway in vivo. Coupled with evidence that Notch-IC can bind to and activate the
LMP2A promoter, we hypothesized that expression of LMP2A results in the constitutive activation of the Notch pathway to auto-regulate its
promoter. Our data indicate that LMP2A constitutively activates the Notch pathway in B cells and epithelial cells. Expression of LMP2A alone is
sufficient to activate its own expression and the amino-terminal signaling domain is required as LMP2B is unable to activate the LMP2A
promoter. In addition, point mutations in tyrosines 31, 101 and 112 each results in a significant decrease in LMP2A promoter activation. Deletion
of the RBP-Jκ consensus sequences results in a significant decrease in promoter activity. The observation that LMP2A activates its own promoter
suggests that LMP2A exploits the Notch pathway in order to control its own expression and may explain EBNA2-independent expression of
LMP2A in EBV-associated malignancies.
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Epstein–Barr virus (EBV) is a ubiquitous human herpesvirus
that infects greater than 90% of the adult population (Kieff and
Rickinson, 2007). Although most EBV infections are asymptom-
atic, disease arises in adolescents as infectiousmononucleosis and
in immunocompromised patients as lymphoproliferative disor-
ders (Rickinson and Kieff, 2007; Thorley-Lawson, 2005;
Thorley-Lawson and Gross, 2004). EBV is associated with
malignancies of lymphoid and epithelial origin, including
Hodgkin's lymphoma (HL), Burkitt's lymphoma (BL) and
nasopharyngeal carcinoma (NPC) (Rickinson and Kieff, 2007).
As is characteristic of herpesviruses, EBV is able to persist in the
human host through the establishment of a lifelong latent
infection. EBV establishes latency in vitro in B lymphocytes by
limiting viral gene expression to a subset of genes which⁎ Corresponding author. Mailing address: Department of Microbiology and
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doi:10.1016/j.virol.2007.10.009includes EBV nuclear antigens 1, 2, 3A, 3B, 3C and LP
(EBNAs), latent membrane protein 1 (LMP1) and latent
membrane protein 2 (LMP2A) (Kieff and Rickinson, 2007).
LMP2A contains a 27-amino-acid carboxy-terminal cyto-
plasmic domain, a 119-amino-acid tyrosine-rich amino-terminal
cytoplasmic domain and 12 hydrophobic transmembrane
domains (Ikeda et al., 2005; Longnecker, 2000; Longnecker
et al., 1991). In the plasma membrane of EBV-infected B cells,
LMP2A localizes to lipid rafts, where it interacts with Src family
protein tyrosine kinases and the tyrosine-rich amino terminus
serves as a substrate for phosphorylation (Ikeda et al., 2005).
LMP2A becomes highly tyrosine phosphorylated upon Lyn (Src
family protein tyrosine kinase) interaction with tyrosine 112.
This initial interaction is required for additional LMP2A tyrosine
phosphorylation (Burkhardt et al., 1992; Fruehling et al., 1998).
Tyrosines 74 and 85 form an immunoreceptor tyrosine-based
activation motif (ITAM), which is required for LMP2A to
constitutively interact with Syk (Fruehling and Longnecker,
1997). By sequestering Lyn and Syk to its amino-terminus,
LMP2A is able to efficiently block B cell receptor signaling,
which may be important for preventing activation of lytic
Table 1
Expression of genes associated with Notch signaling a
Gene Fold change b






Delta (Dlk-1 like) 2.7±1.0
Enhancer of Split (Hes) 2.2±1.0
Suppressor of Hairless (RBP-L) 1.4±0.2
Sel 11 inhibitor of Notch −3.0±0.2
a Data from Portis and Longnecker, 2003.
b Microarray experiments were performed in duplicate using CD19+ bone
marrow (BM) B cells from wild-type and LMP2A transgenic mice (TgE).
Average fold change in gene expression in cells from TgE versus wild-type mice
is shown, along with standard deviation.
c Data confirmed by RT-PCR andWestern blot (Portis and Longnecker, 2003).
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expression of highly immunogenic lytic proteins may allow
EBV-infected cells to evade the immune response.
EBV can also infect epithelial cells and LMP2A expression
is consistently detected in EBV-associated malignancies of
epithelial origin (Raab-Traub, 1992a,b; Raab-Traub et al., 1987;
Young et al., 1988). While the function of LMP2A in epithelial
cells is still under investigation, evidence thus far indicates that
the biology and signaling through LMP2A differs between cell
types. This is likely due to differences in receptor and kinase
expression between B cells and epithelial cells. LMP2A ex-
pression in epithelial cells similarly leads to the constitutive
phosphorylation and activation of the PI3K/Akt pathway
(Morrison et al., 2003; Morrison and Raab-Traub, 2005;
Scholle et al., 2000). However, while in B cells, Y112 and its
interaction with Lyn Src family protein tyrosine kinase is critical
for the phosphorylation and signaling functions of LMP2A
(Fruehling et al., 1996, 1998), LMP2A in epithelial cells relies
on Y101 as well as the ITAM motif (Y74/85) (Lu et al., 2006;
Scholle et al., 1999).
LMP2A has several roles in EBV latent infection, making it a
key target for inhibition of EBV-associated disease. LMP2A is
consistently detected in all EBV-associated malignancies
including HL and NPC. LMP2A transcript has also been
detected in a wide variety of BL cell lines (Konishi et al., 2001;
Rechsteiner et al., 2007; Tao et al., 1998) and three studies have
demonstrated that LMP2A is expressed in fresh BL biopsies
(Bell et al., 2006; Tao et al., 1998; Xue et al., 2002).
Interestingly, in these malignancies, LMP2A is expressed in
the absence of the viral transcriptional activator, EBNA2,
indicating that an alternative mechanism is responsible for its
expression (Rickinson and Kieff, 2007). Microarray analysis of
B lymphocytes from transgenic mice expressing LMP2A has
revealed that LMP2A alters global transcriptional regulation in a
similar manner to that seen in Hodgkin Reed Sternberg (HRS)
cells, implicating a role for LMP2A in its pathogenesis. Of
particular interest, LMP2A expression induces global changes in
transcription factor usage in transgenic mice, downregulating
the activities of E2A, early B cell factor (EBF), and Pax-5 (Portis
et al., 2003; Portis and Longnecker, 2003). These transcription
factors are essential for B cell development and are normally
turned off when Notch signaling is active during lymphopoiesis
(Osborne and Miele, 1999). Similar alterations in transcription
factor usage have also been noted in HL (Cossman et al., 1999;
Jundt et al., 2002a,b; Khan and Coates, 1994; Kuppers et al.,
2002). The increased expression of Notch signaling compo-
nents, RBP-Jκ, Enhancer of Split (Hes) and delta, with
concomitant decreased expression of B-cell-specific transcrip-
tion factors in LMP2A-expressing B cells suggests that LMP2A
is able to activate the Notch pathway in vivo (see Table 1) (Portis
et al., 2003, 2004; Portis and Longnecker, 2003). EBNA2 is a
functional homolog of the cleaved form of Notch (Notch-IC) and
each has the ability to bind and activate RBP-Jκwhich allows for
viral as well as cellular gene transcription. It has been shown
previously that murine Notch1-IC can bind to and induce
transcription from the LMP2A promoter in a reporter assay as
well as using the endogenous promoter. The LMP2A promotercontains two consensus RBP-Jκ sites that are important for its
activation by both Notch-IC and EBNA2 (Gordadze et al., 2001;
Grossman et al., 1994; Hofelmayr et al., 2001,1999; Hsieh et al.,
1997; Ling et al., 1994; Strobl et al., 2000). In conjunction with
these reports, the data from the microarray analysis led to the
novel hypothesis that LMP2A constitutively activates the Notch
pathway in vivo in order to regulate its own expression in the
absence of EBNA2. This novel function of LMP2Awould allow
it to be expressed in EBV-associated malignancies without
expression of other immunogenic viral proteins.
Notch signaling is an evolutionarily conserved pathway that
is necessary for development in a variety of systems, including
lymphopoiesis. Notch receptors are single-pass transmembrane
receptors that undergo proteolytic cleavage upon activation by
ligand binding. Ligands for Notch are cell-associated trans-
membrane proteins and include Delta and Jagged (Osborne and
Miele, 1999). Once cleaved, the intracellular cytoplasmic
domain (Notch-IC) translocates to the nucleus where it interacts
with RBP-Jκ/CBF-1 and converts it from a transcriptional
repressor to an activator (Kawamata et al., 2002; Maillard et al.,
2003; Osborne and Miele, 1999). Notch2 appears to be more
important for B cell function, however both Notch1-IC and
Notch2-IC are functional homologs of EBNA2 (Hsieh et al.,
1997; Souabni et al., 2002). The release of the intracellular
domain of Notch is mediated by γ-secretase (presenilin) activ-
ity, and γ-secretase inhibitors can effectively prevent cleavage
and activation of the Notch pathway. Deregulated expression of
wild-type Notch receptors, ligands and downstream targets have
been described in several cancers such as HL and large cell
lymphomas (Jundt et al., 2002a; Mathas et al., 2006). Notch1
receptors are highly expressed in B-cell derived HRS cells and
activation dramatically increases the rate of proliferation and
decreases susceptibility to chemically induced apoptosis (Jundt
et al., 2002a; Mungamuri et al., 2006). Several γ-secretase
inhibitors are currently in clinical trials for treatment of several
lymphopoietic malignancies including HL.
To gain insight into EBV-associated malignancies, we
sought to determine the mechanism by which LMP2A is
Fig. 1. LMP2A constitutively activates the Notch pathway in B cells and
epithelial cells. (A) BJAB, HaCat and HEK293 cells were transfected with
LMP2A or Notch1-IC as a control. Western blot analysis of whole cell lysates
was performed using antibodies specific for LMP2A (14B7) or Notch1-IC (Cell
Signaling). Equal protein loading was confirmed by probing blots for GAPDH.
A representative blot from at least five independent experiments is shown. For
the BJAB and HaCat stable cell lines, at least two independent clones were
tested, and a representative blot is shown. A 10% gel was used for HEK293 and
BJAB lysates, a 7.5% gel was used for HaCat lysates. (B) Real-time RT-PCR
gene expression analysis was performed using total RNA isolated from BJAB
cells stably expressing LMP2A (pMP2) or empty vector (pBamHyg). Primers
specific for Hes-1, Dtx-1, and Notch1 were utilized along with GAPDH as a
control for RNA levels. Change in gene expression was calculated using the
ΔΔCt method. Experiments were repeated three times with at least two clones
per experiment and the average±standard error is shown. ⁎Indicates pb0.05
compared with vector control. Notch1, p=0.06.
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LMP2A activates the Notch pathway in both B cells and
epithelial cells. Further, expression of LMP2A alone is
sufficient to activate the LMP2A promoter. Signaling through
the amino terminal domain of LMP2A is required for this
function, as LMP2B is unable to confer LMP2A promoter
activity. Point mutations of several conserved tyrosines in
LMP2A also block the ability of LMP2A to auto-regulate its
promoter and suggest that a complex signaling cascade may be
involved in Notch activation. While γ-secretase inhibitors are
unable to block LMP2A promoter activity, deletion of the RBP-
Jκ consensus sequences reduces activation, linking the Notch
pathway to LMP2A auto-regulation. An auto-regulatory loop
for LMP2A suggests a mechanism for EBNA2-independent
LMP2A expression in EBV-associated malignancies.
Results
Activation of the Notch pathway by LMP2A
Cleavage of the Notch receptor occurs following receptor
activation, resulting in the release of the intracellular domain of
Notch (Notch-IC). To determine whether LMP2A constitutively
activates the Notch pathway, whole cell lysates from cells
expressing LMP2A were analyzed using an antibody that
specifically recognizes the intracellular domain of Notch1
following Notch cleavage. Previously described vector control
and LMP2A expressing independent stable clones of BJAB B
cells and HaCat epithelial cells were used (see Materials and
methods). HEK293 cells were transiently transfected with
empty vector (pSG5), LMP2A, LMP2A-HA or Notch1-IC as a
positive control. Western blot analysis of these cells shows that
expression of LMP2A increases the amount of activated Notch1
significantly above basal levels for all three cell types tested
(Fig. 1A). As vector control cells express little to no activated
Notch1, the result is specific to LMP2A expression. To further
confirm that the Notch pathway is specifically activated by
LMP2A, real-time RT-PCR gene expression analysis of Hes-1,
Dtx-1 and Notch1 was performed using RNA from BJAB cells
stably expressing LMP2A (pMP2) or empty vector (pBamHyg).
Hes-1 and Dtx-1 are downstream targets of an activated Notch
receptor. As shown in Fig. 1B, the average change in gene
expression for Hes-1 and Dtx-1 for BJAB cells expressing
LMP2A compared with empty vector controls is 2.6-fold. This
result is statistically significant (pb0.05 by Student's t-test) and
indicates that the Notch pathway is indeed activated in BJAB
cells expressing LMP2A. The change in gene expression for
Hes-1 is similar to that seen in the microarray analysis shown
in Table 1. Notch1 gene expression is similarly increased by
2.5-fold compared with vector control cells, however this result
was not statistically significant by Student's t-test (p=0.06).
Auto-regulation of the LMP2A promoter
As Notch-IC and EBNA2 are functional homologs and both
have been shown to activate the LMP2A promoter, we sought to
determine whether LMP2A uses the ability to constitutivelyactivate Notch to drive transcription from the LMP2A promoter.
To this end, the full-length LMP2A promoter, corresponding to
base pairs 165696–166559 of the B95.8 EBV genome (Zimber-
Strobl et al., 1991), was cloned into the pGL3 Basic reporter
vector, rendering expression of firefly luciferase dependent
upon the LMP2A promoter (LMP2p). HEK293 cells were
transiently transfected with LMP2p along with empty vector (no
activator), LMP2A, LMP2A-HA, LMP2B or vectors expressing
the intracellular domain of Notch1 or Notch2 as controls. Pro-
tein expression from these vectors was confirmed by Western
blot, and a representative blot can be seen in the HEK293 panel
of Fig. 1A. Indeed, expression of LMP2A alone is sufficient to
activate its own promoter (Fig. 2). LMP2A and LMP2A-HA
similarly induce a fourfold increase in the relative luciferase
activity. None of the activators induced firefly luciferase activity
from the promoterless pGL3 Basic reporter vector (data not
Fig. 3. γ-Secretase inhibitors are unable to inhibit LMP2A auto-regulation.
HEK293 cells were transiently transfected with LMP2p and LMP2A in the
presence of 1 μM, 10 μM or 50 μM DAPT or DMSO vehicle control for 18 h
and lysed. Lysates were used to measure luciferase activity (A) or protein
expression by Western blot (B). Luciferase activity for untreated cells was set to
100% and the luciferase activity of DMSO and inhibitor treated cells was
normalized to this value. The average relative luciferase activity from three
independent experiments is shown±standard error. There is no statistically
significant difference between DMSO and inhibitor treated cells. Similar results
were obtained using γ-secretase inhibitor XII (Z-IL-CHO), data not shown.
Fig. 2. LMP2A can auto-activate its promoter in HEK293 cells. A reporter
plasmid expressing firefly luciferase under the control of the full-length LMP2A
promoter (LMP2p) was transiently transfected into HEK293 cells with the
indicated activators. Luciferase was quantified and normalized to an internal
renilla luciferase control. Notch1-IC and Notch2-IC expressing plasmids were
included as a positive control and LMP2B as a negative control. Average fold
induction was calculated by dividing the normalized firefly luciferase value for
each activator by the value obtained with no activator (empty vector). Data
averaged from at least five independent experiments are shown±standard error.
⁎Indicates pb0.05 when compared with wild-type LMP2A.
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with LMP2B lacking the exon encoding the amino-terminal tail
attributed to the signaling capacity of LMP2A. Expression
of LMP2B does not result in the activation of the LMP2p,
indicating that auto-regulation is specific to signaling via the
amino-terminus of LMP2A (Fig. 2).
Inhibitors of Notch cleavage cannot block promoter activation
by LMP2A
γ-Secretase inhibitors block the proteolytic cleavage of the
Notch intracellular domain from the membrane-bound portion
of the receptor and therefore block Notch-mediated transcrip-
tion in the nucleus. To determine whether cleavage of Notch is
required for LMP2A auto-regulation, two γ-secretase inhibitors
were examined. Varying concentrations of inhibitor were added
concomitant with transfection and LMP2p activity assayed after
18 h. As shown in Fig. 3A, addition of increasing concentra-
tions of the inhibitor DAPT did not alter the ability of LMP2A
to activate LMP2p. Similar results were seen using up to 50 μM
of γ-secretase inhibitor XII, Z-IL-CHO. The IC50 for DAPT is
115 nM and the IC50 for Z-IL-CHO is 8–10 μM, therefore the
concentrations used for these experiments are sufficient to block
Notch cleavage. These results were surprising; therefore we
wanted to verify that the inhibitors were in fact blocking
cleavage of Notch. Western blot analysis of Notch-IC ex-
pression was performed using the same lysates as were used for
the luciferase assay. Fig. 3B shows that the amount of Notch1-
IC present in HEK293 cells treated with DAPT decreases as the
concentration of DAPT increases. However, Notch1-IC does
not become completely undetectable, even using an antibody
with limited sensitivity. The bottom band seen in the Western
blot when LMP2A or Notch1-IC is expressed is still present
when LMP2A-expressing cells are treated with inhibitor, while
the intensity of this band is less apparent in vector control cells,
indicating that there is still some constitutively activated Notch
in these cells.Analysis of the requirement for RBP-Jκ sites in LMP2A
auto-regulation
It has been demonstrated that if the RBP-Jκ sites in the
LMP2A minimal promoter are deleted, there is a significant
decrease in responsiveness to murine Notch1-IC (Hofelmayr
et al., 1999). Similar deletion mutations were generated in the
context of the full-length LMP2A promoter–firefly luciferase
reporter plasmid to examine the requirement of the RBP-Jκ sites
for LMP2A auto-regulation. The LMP2A promoter contains
two RBP-Jκ sites, which consist of an 11-bp consensus
sequence, CGTGGGAA (Grossman et al., 1994; Ling et al.,
1994). As shown in Fig. 4, single deletions of the first or second
RBP-Jκ site result in a modest yet statistically significant
(pb0.05 by Student's t-test) decrease in LMP2p activity via
LMP2A and a more dramatic decrease in activity via Notch1-IC
compared to the wild-type promoter. This activity is reduced
further when both sites are deleted, and this decrease is
statistically significant when compared with each single site
deletion. These data indicate that in HEK293 cells, both RBP-Jκ
sites are important for LMP2A auto-regulation. This is in
contrast to previous data which demonstrate that the second
RBP-Jκ site is more important for mNotch1-IC to activate the
minimal LMP2A promoter in B cells (Hofelmayr et al., 1999)
and is likely due to the differences in cell types and promoter
constructs used.
Fig. 4. Both RBP-Jκ sites are important for auto-regulation. Each RBP-Jk site was deleted from the full-length LMP2p. LMP2pΔRBP1 lacks the first RBP-Jκ site
(nucleotides 166,244–166,251 from the B95.8 genome), LMP2pΔRBP2 lacks the second RBP-Jκ site (166,269–166,276) and both RBP-Jκ consensus sites are
deleted in LMP2pΔRBPdel. Promoter constructs were transiently transfected into HEK293 cells with no activator, LMP2A or Notch1-IC as a control. Average fold
induction was calculated as described in Fig. 2 for each promoter. Data averaged from at least three independent experiments are shown±standard error. ⁎Indicates
pb0.05 by Student's t-test compared with the wild-type promoter. ⁎⁎Indicates pb0.05 by Student's t-test compared with each single deletion promoter.
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To begin to elucidate the mechanism by which LMP2A
activates its own promoter, we took advantage of several point
mutants in the amino terminus of LMP2A that have been
characterized previously (Fruehling et al., 1998; Ikeda et al.,
2000). Tyrosines in the amino-terminus of LMP2A have been
shown to interact with signaling proteins that are important for the
function of LMP2A in B cells and epithelial cells. Each mutant
version of LMP2A-HAwas transiently transfected into HEK293
cells and assayed for its ability to activate LMP2p. As mentioned
above, LMP2B was unable to activate the promoter, demonstrat-
ing the requirement for signaling via the amino terminus of
LMP2A. Point mutations of tyrosines 23, 60 and 64 as well as 74/
85 (the ITAMmotif) showed no statistically significant difference
in LMP2p activation compared to wild-type LMP2A-HA. The
PY1PY2 mutant, which inhibits binding of Nedd4 family
ubiquitin ligases, appears to have a slightly increased ability to
activate the promoter. Although not statistically significant, this
increase is likely due to the enhanced LMP2A expression of this
mutant, as has been previously described (Ikeda et al., 2000,
2001). In contrast, tyrosines 31, 101 and 112 have a statistically
significant decrease in LMP2p activity relative to wild-type
LMP2A-HA (Fig. 5A). Western blot analysis for mutant protein
expression demonstrated that each LMP2A construct was present
at equal levels, indicating that the decrease in promoter activity is
not simply due to differences in protein expression. The bottom
panel of Fig. 5B demonstrates the protein expression levels for
each tyrosine mutant typically seen in each experiment. Each of
these tyrosines has been predicted to or demonstrated to activate
signaling pathways and their lack of function in the luciferase
assay indicates that multiple signaling events may converge on
the LMP2p.
LMP2A mutants are tyrosine phosphorylated in HEK293 cells
Tyrosine phosphorylation of LMP2A is required for many of
the functions of LMP2A including the recruitment of varioussignaling molecules and activation of signal transduction
pathways (Fruehling et al., 1996, 1998; Fruehling and Long-
necker, 1997; Ikeda et al., 2000; Lu et al., 2006; Merchant et al.,
2000; Portis and Longnecker, 2004; Scholle et al., 2000; Swart
et al., 2000). In order to determine whether tyrosine phospho-
rylation of LMP2A is important for activation of the LMP2p,
mutant versions of LMP2A-HA were transiently transfected
into HEK293 cells. Western blot analysis of whole cell lysates
was performed with an anti-phosphotyrosine specific antibody.
Fig. 5B indicates that there is no change in the tyrosine phos-
phorylation status of LMP2A-HA mutants in HEK293 cells, as
previously observed (Scholle et al., 2001). The arrow indicates
the band corresponding to phosphorylated LMP2A based on the
molecular weight. These data demonstrate that tyrosine
phosphorylation is not necessarily required for LMP2A auto-
regulation. Western blot analysis was also performed using an
LMP2A specific antibody to ensure that each LMP2A mutant is
properly expressed (bottom panel, Fig. 5B).
Discussion
Prior to this study, the EBNA2-independent expression of
LMP2A remained a mystery. These results demonstrate that
LMP2A activates the Notch pathway in both B cells and
epithelial cells, and exploits this pathway to regulate its own
expression. Other groups have shown that Notch-IC can acti-
vate EBNA2-responsive promoters, including that of LMP2A,
and gel shift analysis has demonstrated that Notch-IC can bind
to RBP-Jκ sites in the LMP2A promoter (Hofelmayr et al.,
1999). That LMP2A can activate the Notch pathway in vivo
provides the missing link in an auto-regulatory loop. It is not
surprising that LMP2A participates in an auto-regulatory loop,
as another EBV oncogenic protein, LMP1, has been shown
previously to activate its own expression through the Stat3
pathway (Chen et al., 2003; Huye et al., 2007; Ning et al., 2003,
2005). LMP2A auto-regulation through the Notch pathway may
explain its EBNA2-independent expression in EBV-associated
malignancies such as HL, NPC and BL.
Fig. 5. Signaling from the amino-terminus of LMP2A is required for promoter activation. (A) LMP2pwas transiently transfected intoHEK293 cellswithwild-typeLMP2A-
HA or various LMP2A point mutants as activators and analyzed for luciferase activity. Firefly luciferase values were normalized to an internal renilla luciferase control and
fold induction calculated compared to no activator. Average fold induction from at least five independent experiments is shown±standard error. ⁎Indicates pb0.05 by
Student's t-test. (B)Whole cell lysates fromHEK293 cells transfectedwith LMP2A-HA or LMP2A point mutants were used forWestern blot analysis. Duplicate blots were
probed with antibodies specific for LMP2A (14B7) or phosphotyrosine (RC20-HRP). A representative blot of three independent experiments is shown.
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promoter that auto-regulation is dependent upon the presence of
both RBP-Jκ sequences. This is in contrast to previous reports,
which showed that in the context of the minimal LMP2A
promoter, the second RBP-Jκ sequence is more important for
activation by mNotch1-IC than the first in BL41-P3HR1 cells
(Hofelmayr et al., 1999). Given several previous reports of
differential signaling capacity of LMP2A depending on the cell
context, it is logical that regulation of the LMP2A promoter also
differs in the different cell types (Fruehling et al., 1996, 1998;
Fruehling and Longnecker, 1997; Morrison et al., 2003;
Morrison and Raab-Traub, 2005). Additionally, the promoter
constructs used here were different than those used by the
Zimber-Strobl laboratory. Our promoter constructs contained
the full-length LMP2A promoter, corresponding to nucleotides
165,696–166,559 of the B95.8 genome, whereas the Zimber-
Strobl laboratory used a construct containing the minimal
LMP2A promoter (EBNA2 response element, −257 to −178
from the start site), thus it is possible that other elements in the
full-length promoter contribute to enhancement of promoteractivity. Deletion of both RBP-Jκ does not completely abolish
promoter activity in our experiments or those done previously
(Hofelmayr et al., 1999), which supports the possibility of other
regulatory elements in the LMP2p that are important for pro-
moter regulation.
While auto-regulation requires the presence of the RBP-Jκ
sites in LMP2p, indirectly demonstrating that the Notch
pathway is indeed responsible for activation, the lack of
inhibition of promoter activity using γ-secretase inhibitors is
perplexing. There are several plausible explanations for this
result. Previous reports have demonstrated that very low levels
of activated Notch are sufficient to activate Notch-responsive
promoters (Schroeter et al., 1998) and regardless of the quantity
of exogenous Notch-IC transfected, the fold transactivation of a
RBP-Jκ reporter construct remained the same even when
Notch-IC protein becomes undetectable by Western blot
(Hofelmayr et al., 1999). Western blot analysis of HEK293
cells transfected with LMP2A showed that even in the presence
of 50 μMDAPT, a small amount of Notch-IC protein remains in
these cells and may be sufficient to maintain promoter activity.
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pathways, such as the PI3K/Akt pathway, participate in
crosstalk with the Notch signaling pathway and can lead to
significantly enhanced transcriptional activation when com-
pared with Notch signaling alone (Liu et al., 2006; McKenzie
et al., 2006). In T cells, T cell receptor activation of PI3K results
in a dramatic increase in the level of activation of downstream
targets of the Notch pathway (McKenzie et al., 2006). It is
tempting to speculate that LMP2A uses its ability to activate
several signaling pathways to activate its own expression,
and that while Notch activation is partially blocked by the
γ-secretase inhibitors, low levels of Notch activity remain and
transcriptional activity at the LMP2A promoter is enhanced
by the ability of LMP2A to activate the PI3K pathway. This
hypothesis is supported by the inability of the LMP2AY31A
mutant to activate the promoter. Tyrosine 31 is predicted to
bind to PI3K based on predicted sequence homology (Long-
necker, 2000), however prior to this report; a phenotype for the
Y31A mutation has not been identified.
An alternative explanation for the lack of inhibition by the
γ-secretase inhibitors is that LMP2A signaling may not induce
an active cleavage event. Instead, it may stabilize cleaved
Notch by sequestering away regulatory proteins such as cbl and
AIP4/Itch/Nedd4 and preventing the degradation of Notch-IC
by the proteasome. This explanation is not without precedence,
as the LANA protein of KSHV, another γ-herpesvirus, has been
recently demonstrated to induce activation of the Notch pathway
by stabilizing the Notch-IC protein, which is normally rapidly
turned over upon phosphorylation and binding of cbl and AIP4
(Carroll et al., 2006; Jehn et al., 2002). LMP2A is also known to
bind to AIP4/Itch and is predicted to bind to Cbl as well (Ikeda
et al., 2000, 2001; Longnecker, 2000). Both of these ubiquitin
ligases are important for the regulation of Notch signaling and
their binding to LMP2A and subsequent sequestration may
result in a stable cleaved Notch protein that can readily activate
responsive promoters. Although Western blot analysis of cells
treated with γ-secretase inhibitors shows small amounts of
cleaved Notch remaining, it remains to be determined whether
Notch2 may be more important in this cell type, as reliable
reagents to detect cleaved Notch2 are not available.
Given the complexity of LMP2A signaling and the context
of an immortalized cell, it is likely that Notch activation is not
necessarily the only mechanism for auto-regulation exploited by
LMP2A. This is supported by our studies and those of the
Zimber-Strobl laboratory which demonstrated that LMP2A
promoter activation is not completely abrogated upon deletion
of both RBP-Jκ sites in the presence of exogenous Notch-IC. In
addition, the RBP-Jκ sites are not sufficient for Notch-IC to
mediate transactivation of the LMP2p, and at least one other site
in the minimal promoter is important for transactivation in both
B cells and epithelial cells (Hofelmayr et al., 1999). Further
support is provided by the mutational analysis of LMP2A,
which indicated that multiple signaling pathways may play a
role in auto-regulation. Signaling through the amino-terminus is
required for LMP2A to mediate its auto-regulatory function
because LMP2B is unable to confer promoter activity. Further,
Y31, Y101 and Y112 each have a statistically significantdecrease in activity, supporting the notion that there is a role for
multiple signaling pathways in LMP2A auto-regulation. As
mentioned above, Y31 may play a role in PI3K signaling. Y101
and Y112 are both important for binding of Src family protein
tyrosine kinases, and therefore may be required to recruit and/or
phosphorylate proteins in the LMP2A signalosome to potentiate
Notch signaling.
As EBNA2 and Notch-IC are functional homologs, one
might predict that LMP2A-mediated activation of the Notch
pathway in EBV-associated malignancies would also lead to the
activation of other EBNA2-responsive genes such as the Cp and
Wp latency promoters. This is not the case, however, as other
EBNA2-responsive genes are not detected in HL, NPC or BL
(Bell et al., 2006; Kieff and Rickinson, 2007; Rickinson and
Kieff, 2007). There is considerable evidence that the EBV
genome is extensively methylated in cell lines exhibiting limited
viral latency. More specifically, the Cp and Wp promoters are
hypermethylated in tumor cell lines and in the latent memory
B cells of seropositive healthy individuals (Ernberg et al.,
1989; Masucci et al., 1989; Paulson et al., 2002; Robertson
and Ambinder, 1997; Schaefer et al., 1997, 1991). Interestingly,
these are the very same environments where the LMP2A
transcript is often detected (Thorley-Lawson, 2005; Thorley-
Lawson and Gross, 2004). Therefore, it is likely that the reason
that LMP2A activation of the Notch pathway does not lead to
activation of other EBNA2-responsive genes involves the
methylation status of the promoters. This explanation assumes
that the LMP2A promoter is hypomethylated, however the
methylation status of the LMP2A promoter has not been deter-
mined, and mechanisms of EBV genomemethylation are not yet
clear. From our data, we propose a model for LMP2A expression
in EBV-associated malignancies where the LMP2A promoter
remains hypomethylated and available for active transcription.
Signaling cascades activated by LMP2A induce the activation of
the Notch pathway which leads to LMP2A promoter activity in
an auto-regulatory loop. This mechanism allows for LMP2A
expression without triggering the expression of other immuno-
genic latent proteins and provides a means for LMP2A to
maintain a latent EBV infection and promote survival of aber-
rantly proliferating cells.
Materials and methods
Cell lines and culture conditions
BJAB is an EBV-negative Burkitt's lymphoma cell line
obtained from ATCC (Rockville, MD) and grown in RPMI
1640 medium supplemented with 10% fetal plex, 1000 U of
penicillin/ml and 1000 μg of streptomycin/ml. Stable BJAB cell
lines have been described previously (Ikeda et al., 2000) and
were maintained in complete RPMI 1640 plus 400 U/ml
hygromycin. Stable HaCat cell lines were generated as
described (Fukuda and Longnecker, 2007) and grown in
DMEM supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 1000 U/ml penicillin, 1000 μg/ml streptomycin
and 400 U/ml hygromycin. pMP2 contains the LMP2A cDNA
cloned into the pBamHyg retroviral vector. HEK293 cells were
264 L.J. Anderson, R. Longnecker / Virology 371 (2008) 257–266grown in DMEM supplemented with 10% fetal plex, 1000 U/ml
penicillin and 1000 μg/ml streptomycin.
Plasmids
The LMP2A promoter (LMP2p), corresponding to nucleo-
tides 165,696–166,559 of the B95.8 genome (Zimber-Strobl
et al., 1991), was PCR amplified and cloned into the pGL3 Basic
plasmid (Promega) as aKpnI/XhoI fragment. Deletion mutations
of the RBP-Jκ sites in the full-length LMP2p were generated
using the Quikchange Mutagenesis kit (Stratagene). All
constructs and mutations were confirmed by sequence analysis.
pRLCMV (Promega) expresses renilla luciferase under the con-
trol of the CMV promoter and is used as an internal transfection
control. pSG5-Notch1-IC and pSG5-Notch2-IC were kindly
provided by Paul Ling. pLMP2A and p-LMP2A-HA have been
described previously (Longnecker et al., 1991). pLMP2A-HA
contains anHA tag at the carboxy-terminus of LMP2A.All point
mutations were generated by PCR-based mutagenesis in the
context of pLMP2A-HA (Fruehling et al., 1998). All DNA used
for experiments was banded twice on CsCl density gradients and
purified by ethanol precipitation.
Transfection and luciferase assays
HEK293 cells were plated in 6-well dishes and transfected
using 15 μl Polyethylenimine (PEI, 1 μg/μl, Polysciences, Inc.)
mixed with 200 μl of serum-free DMEM and 0.1 μg LMP2p,
0.01 μg pRLCMVand 4 μg activator DNA for 10 min at room
temperature. The transfection mixture was then added to each
well containing cells in complete DMEM. Eighteen hours post-
transfection, cells were washed with sterile PBS and lysed with
passive lysis buffer (Promega) for 30-min rocking at room
temperature. Relative luciferase activity was measured with the
Promega Dual Luciferase Reporter Assay System in a
Visibottom 96-well plate using a Victor plate reader according
to the kit instructions. Firefly luciferase values were normalized
for transfection efficiency based on Renilla luciferase activity.
Western blots
HEK293 cells were transfected for 18 h with 4 μg of each
DNA as above. Cells were lysed in buffer containing 50 mM
Tris–HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.1%
SDS, 10% glycerol, 10 mM NaF, 1 mM Na3VO4, 2 mM EDTA,
0.5 mM PMSF, 10 μg/ml pepstatin and 10 μg/ml leupeptin at
107 cells/ml lysis buffer. Lysates were mixed with 5× SDS
sample buffer and heated to 70 °C for 10 min. Proteins were
resolved by SDS-PAGE, transferred to Immobilon-P (Millipore,
Bedford, MA), and blocked with 3% BSA in TBST. Primary
antibodies—rat monoclonal anti-LMP2A 14B7, rabbit poly-
clonal anti-cleaved Notch1 (Cell Signaling), and mouse
monoclonal anti-GAPDH (Abcam) were incubated overnight.
Blots were then probed with the appropriate HRP-conjugated
secondary antibodies and visualized using ECL (Amersham).
To detect phosphotyrosine, RC20-HRP anti-phosphotyrosine
antibody was used (Transduction Laboratories).Inhibitors
γ-Secretase inhibitor IX (DAPT IC50=115 nM) andγ-secretase
inhibitor XII (IC50 8–10 μM)were obtained from Calbiochem and
dissolved in DMSO. Subsequent dilutions were made in media
containing 10% heat-inactivated FBS and inhibitors were added
concomitant with the transfection mixtures.
Real-time RT-PCR
Total RNA from stable BJAB cell lines was isolated using
the RT2qPCR-Grade RNA Isolation Kit (Superarray Biosci-
ence Corporation, Frederick, MD). 5 μg of RNA was reverse
transcribed using the Superarray Bioscience RT2 First Strand
Kit according to kit instructions. 2 μl of template cDNA was
then used in the RT2qPCR Primer Assay-SYBR Green Kit
from Superarray Bioscience with primers specific for human
Hes-1, human Dtx-1, human Notch1 and human GAPDH. PCR
was carried out using the BioRad iQ5 according to kit
instructions. SYBR green fluorescence was detected and
recorded from each well during the annealing step of each
cycle. Ct values were normalized to GAPDH levels. Fold
change in gene expression for each gene of interest was cal-
culated using the ΔΔCt method. Three independent experi-
ments were performed with at least two independent clones per
experiment.
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